mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
出版年份 2017 全文链接
标题
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
作者
关键词
-
出版物
LIVER INTERNATIONAL
Volume 37, Issue 7, Pages 1047-1055
出版商
Wiley
发表日期
2017-01-09
DOI
10.1111/liv.13359
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
- (2015) Bruno Vincenzi et al. PLoS One
- Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
- (2014) Tadaaki Arizumi et al. JOURNAL OF GASTROENTEROLOGY
- Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
- (2014) M. Ronot et al. ONCOLOGIST
- EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation
- (2013) Huzi Li et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
- (2013) Eun Suk Jung et al. JOURNAL OF HEPATOLOGY
- Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma
- (2013) Chang Joon Kim et al. LIVER INTERNATIONAL
- mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
- (2012) H. J. Prajapati et al. ANNALS OF ONCOLOGY
- Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation
- (2012) Beom Kyung Kim et al. EUROPEAN JOURNAL OF CANCER
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
- (2011) Roopinder Gillmore et al. JOURNAL OF HEPATOLOGY
- Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)
- (2010) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started